Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling

Molecular Carcinogenesis

Volumn 54, Issue 9, 2015, Pages 841-852

  Schweiger, Nicole ^a   Hauck, Marlene ^b,c   Steinhoff, Heinrich ^b   Sampl, Sandra ^b   Reifinger, Martin ^a   Walter, Ingrid ^a   Kreilmeier, Theresa ^a,b   Marian, Brigitte ^b   Grusch, Michael ^b   Berger, Walter ^b   Holzmann, Klaus ^b   Kleiter, Miriam ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Comparative analyses; Dog; Fibroblast growth factor receptor; Human; Sarcoma; Tyrosine kinase inhibitor

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PD 166866; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ISOPROTEIN; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; INFECTION; INTRACELLULAR SIGNALING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SARCOMA CELL LINE; SOFT TISSUE SARCOMA; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DOG; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; SARCOMA; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CANIS FAMILIARIS;

ANIMALS; CELL LINE, TUMOR; DOGS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SARCOMA; SIGNAL TRANSDUCTION; UREA;

EID: 84938955728     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22155     Document Type: Article

References (49)

1. Sleeman M, Fraser J, McDonald M, et al. Identification of a new fibroblast growth factor receptor FGFR5. Gene 2001; 271:171-182.
2. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10:116-129.
3. Zhuang L, Falquet L, Trueb B. Genome-wide comparison of FGFRL1 with structurally related surface receptors. Exp Ther Med 2010; 1:161-168.
4. Holzmann K, Grunt T, Heinzle C, et al. Alternative splicing of fibroblast growth factor receptor IgIII loops in cancer. J Nucleic Acids 2012; 2012:950508.
5. Beenken A, Mohammadi M. The FGF family: Biology, pathophysiology and therapy. Nat Rev Drug Discov 2009; 8:235-253.
6. Ornitz DM, Xu J, Colvin JS, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996; 271:15292-15297.
7. Heinzle C, Gsur A, Hunjadi M, et al. Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis. Cancer Res 2012; 72:5767-5777.
8. Sonvilla G, Allerstorfer S, Heinzle C, et al. Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration. Br J Cancer 2010; 102:1145-1156.
9. Jang MH, Kim EJ, Choi Y, et al. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. Breast Cancer Res 2012; 14:R115.
10. di Martino E, Tomlinson DC, Knowles MA. A decade of FGF receptor research in bladder cancer: Past, present, and future challenges. Adv Urol 2012; 2012:429213.
11. Huynh H, Ngo VC, Fargnoli J, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008; 14:6146-6153.
12. Fischer H, Taylor N, Allerstorfer S, et al. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther 2008; 7:3408-3419.
13. Heist RS, Mino-Kenudson M, Sequist LV, et al. FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol 2012; 7:1775-1780.
14. Metzner T, Bedeir A, Held G, et al. Fibroblast growth factor receptors as therapeutic targets in human melanoma: Synergism with BRAF inhibition. J Invest Dermatol 2011; 131:2087-2095.
15. Allerstorfer S, Sonvilla G, Fischer H, et al. FGF5 as an oncogenic factor in human glioblastoma multiforme: Autocrine and paracrine activities. Oncogene 2008; 27:4180-4190.
16. Heinzle C, Sutterluty H, Grusch M, Grasl-Kraupp B, Berger W, Marian B. Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy. Expert Opin Ther Targets 2011; 15:829-846.
17. Knights V, Cook SJ. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 2010; 125:105-117.
18. Crose LE, Etheridge KT, Chen C, et al. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res 2012; 18:3780-3790.
19. Ishibe T, Nakayama T, Okamoto T, et al. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: Potential application of signal inhibitors to molecular target therapy. Clin Cancer Res 2005; 11:2702-2712.
20. Morimoto Y, Ozaki T, Ouchida M, et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 2003; 98:2245-2250.
21. Taylor JG, Cheuk AT, Tsang PS, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 2009; 119:3395-3407.
22. Liptak JM, Forrest L. Soft tissue sarcomas. In: Withrow SJ, Vail DM, editors. Withrow & MacEwens's small animal clinical oncology. 4th edition. St. Louis, MO: Sauners Elsevier; 2007. pp. 425-454.
23. Ehrhart N. Soft-tissue sarcomas in dogs: A review. J Am Anim Hosp Assoc 2005; 41:241-246.
24. Jane MJ, Hughes PJ. Disease incidence and results of extremity lesion treatment: mersey region soft tissue sarcomas (1975-1985). Sarcoma 1998; 2:89-96.
25. Kotilingam D, Lev DC, Lazar AJ, Pollock RE. Staging soft tissue sarcoma: Evolution and change. CA Cancer J Clin 2006; 56:282-291.
26. Khatri VP, Goodnight JE, Jr. Extremity soft tissue sarcoma: Controversial management issues. Surg Oncol 2005; 14:1-9.
27. Gordon IK, Khanna C. Modeling opportunities in comparative oncology for drug development. ILAR J 2010; 51:214-220.
28. Hauck ML, LaRue SM, Petros WP, et al. Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Clin Cancer Res 2006; 12:4004-4010.
29. Dobson JM, Samuel S, Milstein H, Rogers K, Wood JL. Canine neoplasia in the UK: Estimates of incidence rates from a population of insured dogs. J Small Anim Pract 2002; 43:240-246.
30. Wergin MC. Effect of ionizing radiation molecular parameters in spontaneous canine tumors and canine tumor cell lines. PhD Thesis. Zurich: University of Zurich; 2007.
31. Snyder SA, Linder K, Hedan B, Hauck ML. Establishment and characterization of a canine soft tissue sarcoma cell line. Vet Pathol 2011; 48:482-485.
32. Knapp DW, Chan TC, Kuczek T, Reagan WJ, Park B. Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. Am J Vet Res 1995; 56:801-805.
33. Panek RL, Lu GH, Dahring TK, et al. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase. J Pharmacol Exp Ther 1998; 286:569-577.
34. Sampl S, Pramhas S, Stern C, Preusser M, Marosi C, Holzmann K. Expression of telomeres in astrocytoma WHO grade 2 to 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade. Transl Oncol 2012; 5:56-65.
35. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:e45.
36. Berger W, Elbling L, Hauptmann E, Micksche M. Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. Int J Cancer 1997; 73:84-93.
37. Grusch M, Losert A, Lackner A, Deli A, Herbacek I, Holzmann K. Microscopic analysis of adenoviral decontamination using GFP adenovirus with comparable sensitivity to flow cytometry. Methods Mol Biol 2009; 515:125-135.
38. de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics 2004; 20:1453-1454.
39. Saldanha AJ. Java Treeview-Extensible visualization of microarray data. Bioinformatics 2004; 20:3246-3248.
40. Steinberg F, Zhuang L, Beyeler M, et al. The FGFRL1 receptor is shed from cell membranes, binds fibroblast growth factors (FGFs), and antagonizes FGF signaling in Xenopus embryos. J Biol Chem 2010; 285:2193-2202.
41. Matsubara A, Kan M, Feng S, McKeehan WL. Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2. Cancer Res 1998; 58:1509-1514.
42. Ricol D, Cappellen D, El Marjou A, et al. Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 1999; 18:7234-7243.
43. Schweigerer L, Neufeld G, Friedman J, Abraham JA, Fiddes JC, Gospodarowicz D. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 1987; 325:257-259.
44. Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 1997; 3:887-893.
45. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16:159-178.
46. Muller-Tidow C, Diederichs S, Bulk E, et al. Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res 2005; 65:1778-1782.
47. Gozgit JM, Wong MJ, Moran L, et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 2012; 11:690-699.
48. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68:4774-4782.
49. Garofalo A, Naumova E, Manenti L, et al. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin Cancer Res 2003; 9:3476-3485.